Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD: Progression‐free survival
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Small‐volume residual disease (SVRD) < 1 cm vs NMRD Progression‐free survival: Median length of · women with advanced EOC after PDS Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty). Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian… (2022) · Cochrane Headline outcomes only | HR 1.88 [1.63, 2.16] | 10 studies · 6596 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.